CURAPHARMA
CURAPHARMA has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €135k and a net result of €7k. Equity is growing by ~8.5% per year across the filed fiscal years. Its solvency ranks better than 69% of 480 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
| Equity | €135k |
| Net result | €7k |
| Better than sector | 69% |
| Active | 20 yrs |
Strong profile, led by stability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 38.3% | 21.2% | |
| Net result | €7k | €32k | |
| Equity | €135k | €163k | |
| Gross operating margin | €17k | €281k | |
| Total assets | €352k | €900k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | €17k | €23k | €44k | €27k |
| Net profit | €7k | €10k | €32k | €14k |
| Cash flow | €11k | €15k | €36k | €19k |
| Staff costs | - | - | - | - |
| Income taxes | €2k | €3k | €5k | €5k |
| Dividends | - | - | - | - |
| Total assets | €352k | €387k | €383k | €351k |
| Equity | €135k | €128k | €118k | €101k |
| Debt | €217k | €259k | €265k | €250k |
| of which ≤ 1y | €215k | €255k | €262k | €247k |
| of which > 1y | - | - | - | - |
| Working capital | €127k | €117k | €103k | €87k |
| Employees (FTE) | - | - | - | - |
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 1.59 | 1.46 | 1.39 | 1.35 |
| Quick ratio | 0.90 | 0.85 | 0.84 | 0.77 |
| Working capital ratio | 36.1% | 30.2% | 27.0% | 24.8% |
| Solvency | 38.3% | 33.1% | 30.8% | 28.9% |
| Debt / equity | 1.61 | 2.02 | 2.24 | 2.46 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 4.55 | 4.62 | 14.42 | 5.86 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 2.0% | 2.5% | 8.2% | 4.1% |
| ROE | 5.2% | 7.7% | 26.7% | 14.2% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Full annual accounts (24 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €352k | €387k | €383k | €351k |
| Fixed assets | 21/28 | €10k | €14k | €18k | €17k |
| Tangible fixed assets | 22/27 | €9k | €13k | €17k | €16k |
| Financial fixed assets | 28 | €951 | €951 | €951 | €951 |
| Current assets | 29/58 | €342k | €372k | €365k | €334k |
| Stocks & contracts in progress | 3 | €148k | €155k | €146k | €143k |
| Amounts receivable within one year | 40/41 | €133k | €117k | €110k | €124k |
| Cash & bank | 54/58 | €61k | €99k | €109k | €66k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €352k | €387k | €383k | €351k |
| Equity | 10/15 | €135k | €128k | €118k | €101k |
| Contributions / capital | 10/11 | €12k | €12k | €12k | €12k |
| Reserves | 13 | €42k | €42k | €42k | €42k |
| Accumulated profits (losses) | 14 | €80k | €73k | €63k | €47k |
| Amounts payable | 17/49 | €217k | €259k | €265k | €250k |
| Amounts payable within one year | 42/48 | €215k | €255k | €262k | €247k |
| Trade debts payable within one year | 44 | €113k | €118k | €90k | €77k |
| Income statement | |||||
| Gross operating margin | 9900 | €17k | €23k | €45k | €27k |
| Operating result | 9901 | €13k | €18k | €40k | €22k |
| Financial income | 75 | €357 | €401 | €522 | €1k |
| Financial charges | 65 | €4k | €5k | €3k | €5k |
| Result before taxes | 9903 | €9k | €13k | €37k | €19k |
| Income taxes | 67/77 | €2k | €3k | €5k | €5k |
| Net result for the period | 9904 | €7k | €10k | €32k | €14k |
| Result to be appropriated | 9905 | €7k | €10k | €32k | €14k |
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 22-12-2005 |
| Status | Active |
| Postal code | 1930 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23094D0359/00Z000 | Flanders | 174 m² | 1 · 105 m² | 12.6 m · 3 fl. |
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
06-12-2022 Change in the board of directors
Technical details
{
"events": [
{
"kind": "substantive_delegation",
"role": "gedelegeerd_bestuurder",
"person": null,
"reason": null,
"subkind": "additional",
"via_org": {
"kbo": null,
"name": "Accounting \u0026 Tax Partners",
"address": "3001 Leuven (Heverlee), Grauwmeer 1 C",
"country": "BE",
"legal_form": null
},
"statutory": "niet_statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Een bijzondere volmacht met recht van indeplaatsstelling en met de bevoegdheid om ieder afzonderlijk te handelen werd verleend aan de besloten vennootschap \u0022Accounting \u0026 Tax Partners",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "substantive_delegation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "Tom LAMOTE",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "additional",
"via_org": null,
"statutory": "niet_statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "De vergadering nam akte van de bevestiging van de aanstelling van de heer Tom LAMOTE, door het bestuursorgaan van de Besloten Vennootschap \u0022KRITO PHARMA\u0022, als haar vaste vertegenwoordiger",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Fabienne GENICOT",
"firm_city": null,
"firm_name": "JADOUL, KESTELYN \u0026 GENICOT",
"office_city": "Tervuren",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2022-12-06",
"filing_date": "2022-12-02",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2022-11-29",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0878.122.786",
"name_full": "CURAPHARMA",
"legal_form": "BV"
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"uitgifte van de akte dd. 29 november 2022",
"geco\u00F6rdineerde statuten"
],
"corrected_publication_numac": null
}| Legal nameNL | CURAPHARMA |